Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05890118
Registration number
NCT05890118
Ethics application status
Date submitted
25/05/2023
Date registered
6/06/2023
Date last updated
11/01/2024
Titles & IDs
Public title
Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule
Query!
Scientific title
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of RT-111- RaniPill Capsule Containing Ustekinumab - Administered Orally to Healthy Volunteers
Query!
Secondary ID [1]
0
0
RT-111-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Stelara
Combination Product - RT-111 (0.5mg)
Combination Product - RT-111 (0.75mg)
Active Comparator: SC Group - In up to 15 volunteers, 0.5mg of Stelara will be administered subcutaneously and serial blood samples will be collected for PK analysis.
Experimental: RT-111 Group 1 - In up to 20 volunteers, a RaniPill capsule containing 0.5mg of ustekinumab will be administered and serial blood samples will be collected for PK analysis.
Experimental: RT-111 Group 2 - In up to 20 volunteers, a RaniPill capsule containing 0.75mg of ustekinumab will be administered and serial blood samples will be collected for PK analysis.
Treatment: Drugs: Stelara
A commercial formulation of ustekinumab for SC control (0.5mg)
Combination Product: RT-111 (0.5mg)
RaniPill capsule containing ustekinumab with a dose of 0.5mg
Combination Product: RT-111 (0.75mg)
RaniPill capsule containing ustekinumab with a dose of 0.75mg
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Combination Product
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Evaluate Cmax of ustekinumab administered via the RaniPill capsule
Query!
Assessment method [1]
0
0
To obtain PK profiles of single doses of ustekinumab given via RaniPill™ capsule in healthy volunteers over a dose range of 0.5 to 0.75mg. Cmax of ustekinumab will be calculated from the PK profiles.
Query!
Timepoint [1]
0
0
Within 60 days after ingesting the device
Query!
Primary outcome [2]
0
0
Evaluate Tmax of ustekinumab administered via the RaniPill capsule
Query!
Assessment method [2]
0
0
To obtain PK profiles of single doses of ustekinumab given via RaniPill™ capsule in healthy volunteers over a dose range of 0.5 to 0.75mg. Cmax of ustekinumab will be calculated from the PK profiles.
Query!
Timepoint [2]
0
0
Within 60 days after ingesting the device
Query!
Primary outcome [3]
0
0
Evaluate AUC of ustekinumab administered via the RaniPill capsule
Query!
Assessment method [3]
0
0
To obtain PK profiles of single doses of ustekinumab given via RaniPill™ capsule in healthy volunteers over a dose range of 0.5 to 0.75mg. Cmax of ustekinumab will be calculated from the PK profiles.
Query!
Timepoint [3]
0
0
Within 60 days after ingesting the device
Query!
Secondary outcome [1]
0
0
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of RT-111)
Query!
Assessment method [1]
0
0
Monitoring and recording of adverse events possibly related to RT-111.
Query!
Timepoint [1]
0
0
Within 60 days after ingesting the device
Query!
Eligibility
Key inclusion criteria
1. Participant is ambulatory and between 18 to 65 years of age
2. Body mass index between 19- 32 kg/m2
3. RT-111 ONLY: Female volunteers must be non-menstruating at dosing
4. Female volunteers must be non-pregnant or non-lactating during study participation
5. Male volunteers must agree to use acceptable forms of contraception, if necessary, and
to not donate sperm during study participation.
6. Have suitable venous access for blood sampling.
7. In good general health confirmed by medical history, physical examination, and absence
of clinically important laboratory abnormalities per Investigator's judgment
8. Participant understands the nature of the study, is willing to comply with protocol
defined evaluations, and provide written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. History of intolerance to Stelara® or its constituents
2. Have a known history of previous exposure to IL-12 and/or IL-23 inhibitors.
3. History (=10 years) or presence of disease determined by the PI to be clinically
significant including:
1. gastrointestinal (including diverticulitis, stomach ulcers, inflammatory
intestinal disease, gastrointestinal perforations/fistulae/intra-abdominal
abscess).
2. any other internal, non-gastrointestinal fistulae that is at an increased risk of
bleeding.
3. hematological (including pancytopenia, aplastic anemia, or blood dyscrasia).
4. renal, endocrine, hepatic, pulmonary (childhood asthma is allowed), neurologic,
psychiatric, metabolic (including known diabetes mellitus), or
5. allergic disease excluding mild asymptomatic seasonal and food allergies.
4. Have a history of prolonged immunosuppressant therapy or photochemotherapy treatment.
5. Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body
area), open sore or branding that, in the opinion of the Investigator, would interfere
with interpretation of skin adverse reactions.
6. Have a history of and/or current cardiac disease defined as one of the following:
1. History of congestive heart failure; angina pectoris requiring anti-anginal
medication.
2. Evidence of transmural infarction on ECG.
3. History of sustained hypertension (systolic > 180 mmHg and/or diastolic > 100
mmHg), hypertensive crisis or hypertension encephalopathy.
4. Clinically significant valvular heart disease or severe arterial thromboembolic
events.
7. Have a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C
virus, human immunodeficiency virus (HIV) or history of active, latent, or
inadequately treated tuberculosis (TB) infection
8. Positive serum pregnancy test for women of childbearing potential at the Screening
visit or positive urine pregnancy test with confirmatory serum pregnancy test prior to
dosing.
9. Females who are breastfeeding.
10. Have a history of cancer including lymphoma, leukemia, and skin cancer (volunteers
with a maximum of 3 surgically resected basal cell carcinoma or squamous cell
carcinoma are permitted).
11. Have an illness within 30 days prior to screening, or prior to dosing, that has not
resolved and is classed as clinically significant by the Investigator.
12. Any current active infections, including localized infections, or any recent history
(within 1 week prior to study drug administration) of active infections (including
severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] based on a positive
COVID-19 polymerase chain reaction [PCR] nasopharyngeal swab test), cough or fever, or
a history of recurrent or chronic infections.
13. Have had major surgery within 30 days prior to screening or will have an operation
between screening and the end of study visit, or have any unhealed wound, including
wound dehiscence and wound healing complications requiring medical intervention.
14. Have received live vaccines during the past 4 weeks before Screening or have the
intention to receive vaccination during the study period or within 13 weeks after
dosing.
15. Have received a Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to dose
administration or is planning to receive a BCG vaccination within 1 year following
dose administration.
16. History of alcohol abuse (defined as more than 12 standard drinks per week or more
than 4 standard drinks on > 3 days per week; where 1 standard drink is 10 g of pure
alcohol and is equivalent to 285 mL beer [4.9% Alc./Vol], 100 mL wine [12% Alc./Vol],
30 mL spirit [40% Alc./Vol]) within 12 weeks prior to the screening visit.
17. Positive drug or alcohol test results. In the event the urinary drug test is positive,
the test may be repeated once (at the discretion of the PI) to confirm eligibility.
18. Donation of more than 500 mL of blood within 4 weeks prior to drug administration.
19. Abnormal or irregular bowel movements, in the opinion of the Investigator.
20. Any history of non-traumatic hemorrhage (i.e., any hemorrhage requiring medical
intervention) or any condition which may increase bleeding risk including clotting
disorders, thrombocytopenia (platelet count < 150,000 per µL) or an international
normalized ratio higher than 1.5.
21. Impaired liver function as determined by a serum alanine aminotransferase (ALT) and/or
aspartate aminotransferase (AST)> 1.5 x upper limit of normal (ULN). Participants with
values between ULN and 1.5 x ULN may be included in the study if considered not
clinically significant by the Investigator.
22. Treatment with non-topical medications (including over-the-counter [OTC] medications
and herbal remedies such as St. John's Wort extract) within 7 days or 5 half-lives of
the drug (whichever is longer) prior to CTM administration, with the exception of
multivitamins, vitamin C, food supplements and a limited amount of acetaminophen (up
to 2 g in 24 hours, but <1 g in 4 hours) or ibuprofen (<1.2 g per day), which may be
used throughout the study.
23. Participants on a higher than the lowest approved therapeutic dose regimen of proton
pump inhibitors (see Section 9.1.6 for details)
24. Participants on a H2 receptor antagonists (e.g., famotidine, cimetidine)
25. Consumption of any foods containing poppy seeds within 48 hours prior to screening and
admission to the clinical center.
26. Presence of proteinuria (other than trace amounts i.e., +, ++/+++).
27. Personal history of venous thromboembolic events or idiopathic venous thromboembolic
events in a first degree relative.
28. Excessive smoking habit (more than 5 cigarettes/day) or drug consumption
29. Other clinically relevant findings per physical or laboratory examination or symptoms
of a clinically relevant illness 3 weeks prior to the dose of study drug.
30. Participation in a clinical study with an IP dosing within 60 days or 5 half-lives of
that IP (if known), whichever is longer, prior to IP administration in the current
study.
31. History which, in the investigator's judgement, makes the participant ineligible or
exposes the participant to unacceptable risks
32. Low likelihood, in the Investigator's judgment, to complete the study as required per
study plan
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/08/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
28/11/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
55
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Nucleus Network - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
RANI Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A prospective, single-center, open-label, phase 1 study evaluating the pharmacokinetics (PK)
of ustekinumab administered via the RaniPill™ capsule ("RT-111").
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05890118
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Arvinder Dhalla, PhD
Query!
Address
0
0
RANI Therapeutics
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05890118
Download to PDF